Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03361865




Registration number
NCT03361865
Ethics application status
Date submitted
29/11/2017
Date registered
5/12/2017
Date last updated
16/12/2021

Titles & IDs
Public title
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Scientific title
A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Secondary ID [1] 0 0
KEYNOTE-672/ECHO-307
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
UC (Urothelial Cancer) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Epacadostat
Treatment: Drugs - Placebo

Experimental: Pembrolizumab 200 mg + epacadostat 100 mg BID - Pembrolizumab + epacadostat

Active comparator: Pembrolizumab 200 mg + placebo BID - Pembrolizumab + placebo


Treatment: Drugs: Pembrolizumab
Pembrolizumab administered intravenously every 3 weeks.

Treatment: Drugs: Epacadostat
Epacadostat administered orally twice daily.

Treatment: Drugs: Placebo
Matching placebo administered orally twice daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo
Timepoint [1] 0 0
Week 9
Secondary outcome [1] 0 0
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo as Measured by Number of Participants Experiencing Adverse Events (AEs)
Timepoint [1] 0 0
Up to approximately 25 months
Secondary outcome [2] 0 0
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo as Measured by Number of Participants Discontinuing Study Treatment Due to AE
Timepoint [2] 0 0
Up to approximately 25 months

Eligibility
Key inclusion criteria
* Histologically or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.
* Measurable disease based on RECIST v1.1.
* Be considered ineligible to receive cisplatin-based combination therapy, based on protocol-defined criteria.
* Have provided tissue for PD-L1 analysis from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
* Have received no prior systemic chemotherapy for advanced/unresectable (inoperable) or metastatic urothelial cancer.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 14 days prior to randomization.
* Adequate organ function per protocol-defined criteria.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Disease that is suitable for local therapy administered with curative intent.
* Known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
* Active autoimmune disease that has required systemic treatment in past 2 years.
* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
* Known history of or is positive for active hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or has active hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.
* History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.
* History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
* Use of protocol-defined prior/concomitant therapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/08/2020
Sample size
Target
Accrual to date
Final
93
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [2] 0 0
Southern Medical Day Care Centre - Wollongong
Recruitment hospital [3] 0 0
Austin Health-Austin Hospital - Heidelberg
Recruitment hospital [4] 0 0
Adelaide Cancer Centre - Kurralta Park
Recruitment hospital [5] 0 0
Macquarie University Hospital - Macquarie Park
Recruitment postcode(s) [1] 0 0
2298 - Waratah
Recruitment postcode(s) [2] 0 0
2500 - Wollongong
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
2109 - Macquarie Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Belgium
State/province [17] 0 0
Bruxelles
Country [18] 0 0
Belgium
State/province [18] 0 0
Charleroi
Country [19] 0 0
Belgium
State/province [19] 0 0
Gent
Country [20] 0 0
Belgium
State/province [20] 0 0
Haine-Saint-Paul
Country [21] 0 0
Belgium
State/province [21] 0 0
Sint-Niklaas
Country [22] 0 0
Belgium
State/province [22] 0 0
Wilrijk
Country [23] 0 0
Canada
State/province [23] 0 0
New Brunswick
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
France
State/province [26] 0 0
Angers
Country [27] 0 0
France
State/province [27] 0 0
Besançon
Country [28] 0 0
France
State/province [28] 0 0
Bordeaux
Country [29] 0 0
France
State/province [29] 0 0
Clermont-Ferrand
Country [30] 0 0
France
State/province [30] 0 0
Marseille
Country [31] 0 0
France
State/province [31] 0 0
Nancy
Country [32] 0 0
France
State/province [32] 0 0
Paris
Country [33] 0 0
France
State/province [33] 0 0
Pierre-Bénite
Country [34] 0 0
France
State/province [34] 0 0
Reims
Country [35] 0 0
France
State/province [35] 0 0
Strasbourg
Country [36] 0 0
France
State/province [36] 0 0
Toulouse
Country [37] 0 0
France
State/province [37] 0 0
Tours
Country [38] 0 0
France
State/province [38] 0 0
Villejuif
Country [39] 0 0
Germany
State/province [39] 0 0
Schleswig Holstein
Country [40] 0 0
Germany
State/province [40] 0 0
Duesseldorf
Country [41] 0 0
Germany
State/province [41] 0 0
Essen
Country [42] 0 0
Germany
State/province [42] 0 0
Hamburg
Country [43] 0 0
Germany
State/province [43] 0 0
Jena
Country [44] 0 0
Germany
State/province [44] 0 0
Magdeburg
Country [45] 0 0
Germany
State/province [45] 0 0
Muenchen
Country [46] 0 0
Germany
State/province [46] 0 0
Trier
Country [47] 0 0
Germany
State/province [47] 0 0
Tuebingen
Country [48] 0 0
Ireland
State/province [48] 0 0
Cork
Country [49] 0 0
Ireland
State/province [49] 0 0
Dublin
Country [50] 0 0
Ireland
State/province [50] 0 0
Galway
Country [51] 0 0
Ireland
State/province [51] 0 0
Limerick
Country [52] 0 0
Ireland
State/province [52] 0 0
Waterford
Country [53] 0 0
Israel
State/province [53] 0 0
Be'er Sheva
Country [54] 0 0
Israel
State/province [54] 0 0
Haifa
Country [55] 0 0
Israel
State/province [55] 0 0
Kfar Saba
Country [56] 0 0
Israel
State/province [56] 0 0
Petach-Tikwa
Country [57] 0 0
Israel
State/province [57] 0 0
Ramat Gan
Country [58] 0 0
Israel
State/province [58] 0 0
Tel Aviv
Country [59] 0 0
Israel
State/province [59] 0 0
Zerifin
Country [60] 0 0
Italy
State/province [60] 0 0
Arezzo
Country [61] 0 0
Italy
State/province [61] 0 0
Bari
Country [62] 0 0
Italy
State/province [62] 0 0
Meldola
Country [63] 0 0
Italy
State/province [63] 0 0
Milan
Country [64] 0 0
Italy
State/province [64] 0 0
Napoli
Country [65] 0 0
Italy
State/province [65] 0 0
Padova
Country [66] 0 0
Japan
State/province [66] 0 0
Aichi
Country [67] 0 0
Japan
State/province [67] 0 0
Chiba
Country [68] 0 0
Japan
State/province [68] 0 0
Ibaraki
Country [69] 0 0
Japan
State/province [69] 0 0
Nara
Country [70] 0 0
Japan
State/province [70] 0 0
Osaka
Country [71] 0 0
Japan
State/province [71] 0 0
Yamaguchi
Country [72] 0 0
Japan
State/province [72] 0 0
Tokushima
Country [73] 0 0
Japan
State/province [73] 0 0
Tokyo
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Daejeon
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Seoul
Country [76] 0 0
Netherlands
State/province [76] 0 0
Brabant
Country [77] 0 0
Netherlands
State/province [77] 0 0
Amsterdam
Country [78] 0 0
Netherlands
State/province [78] 0 0
Eindhoven
Country [79] 0 0
Netherlands
State/province [79] 0 0
Groningen
Country [80] 0 0
Netherlands
State/province [80] 0 0
Rotterdam
Country [81] 0 0
Poland
State/province [81] 0 0
Bielsko-Biala
Country [82] 0 0
Poland
State/province [82] 0 0
Jelenia Góra
Country [83] 0 0
Poland
State/province [83] 0 0
Katowice
Country [84] 0 0
Poland
State/province [84] 0 0
Komorowice
Country [85] 0 0
Poland
State/province [85] 0 0
Otwock
Country [86] 0 0
Poland
State/province [86] 0 0
Siedlce
Country [87] 0 0
Poland
State/province [87] 0 0
Szczecin
Country [88] 0 0
Poland
State/province [88] 0 0
Warszawa
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Leningrad Region, Vsevolozhsky District
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Ivanovo
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Moscow
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Ryazan
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Saint Petersburg
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ufa
Country [95] 0 0
Spain
State/province [95] 0 0
A Coruña
Country [96] 0 0
Spain
State/province [96] 0 0
Badajoz
Country [97] 0 0
Spain
State/province [97] 0 0
Barcelona
Country [98] 0 0
Spain
State/province [98] 0 0
Hospitalet de Llobregat
Country [99] 0 0
Spain
State/province [99] 0 0
Lugo
Country [100] 0 0
Spain
State/province [100] 0 0
Manresa
Country [101] 0 0
Spain
State/province [101] 0 0
Sabadell
Country [102] 0 0
Spain
State/province [102] 0 0
Sevilla
Country [103] 0 0
Taiwan
State/province [103] 0 0
Beitou
Country [104] 0 0
Taiwan
State/province [104] 0 0
Kaohsiung
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taichung
Country [106] 0 0
Taiwan
State/province [106] 0 0
Tainan
Country [107] 0 0
Taiwan
State/province [107] 0 0
Taipei
Country [108] 0 0
Ukraine
State/province [108] 0 0
Dnipropetrovsk
Country [109] 0 0
Ukraine
State/province [109] 0 0
Kharkiv
Country [110] 0 0
Ukraine
State/province [110] 0 0
Kyiv
Country [111] 0 0
Ukraine
State/province [111] 0 0
Odesa
Country [112] 0 0
Ukraine
State/province [112] 0 0
Sumy
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Surrey
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Glasgow
Country [115] 0 0
United Kingdom
State/province [115] 0 0
London
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Plymouth
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Sunderland

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Incyte Corporation
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.
Trial website
https://clinicaltrials.gov/study/NCT03361865
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark Jones, MD
Address 0 0
Incyte Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03361865